Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Novel Tubgcp4 murine models of microcephaly and chorioretinopathy
Author Affiliations & Notes
  • Maya Helms
    Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States
  • Alyssa Ashleigh Dreffs
    University of Michigan W K Kellogg Eye Center, Ann Arbor, Michigan, United States
  • Renee Christine Ryals
    Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States
  • David A Antonetti
    University of Michigan W K Kellogg Eye Center, Ann Arbor, Michigan, United States
  • Lesley Everett
    Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States
  • Footnotes
    Commercial Relationships   Maya Helms None; Alyssa Dreffs None; Renee Ryals None; David Antonetti None; Lesley Everett None
  • Footnotes
    Support  Foundation Fighting Blindness Career Development Award (PI Lesley Everett)
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 6042. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Maya Helms, Alyssa Ashleigh Dreffs, Renee Christine Ryals, David A Antonetti, Lesley Everett; Novel Tubgcp4 murine models of microcephaly and chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2024;65(7):6042.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Tubulin γ complex protein 4 (TUBGCP4) variants result in microcephaly, chorioretinopathy, and abnormal retinal vascular development in an autosomal recessive manner. TUBGCP4 is a component of the gamma-tubulin ring complex, which is necessary for microtubule nucleation in cells. Li et al. reported that homozygous Tubgcp4 knockout (KO) results in murine embryonic lethality, and that Tubgcp4+/- mice are haplo-insufficient, which is not observed in humans. Thus, viable in vivo models of TUBGCP4 deficiency are needed to define its role in development.

Methods : Mice heterozygous for a novel CRISPR-generated Tubgcp4KO allele were intercrossed embryos were harvested at multiple timepoints. A “gene trap with conditional potential” allele (Tubgcp4cgt) with exon 6 flanked by loxP sites was also generated, which facilitates creation of a conditional Tubgcp4fl “floxed” allele for tissue-specific Tubgcp4 deletion. A χ2 test was used to evaluate deviation from expected Mendelian ratios. Murine fundus photography, optical coherence tomography (OCT), and electroretinograms (ERG) were performed. Retinal flat mounts were stained with an endothelial marker.

Results : Intercrosses of Tubgcp4KO/+ mice produced no Tubgcp4KO/KO mice, demonstrating embryonic lethality (p<0.0005) with loss of Tubgcp4KO/KO mice prior to embryonic day 9.5 (p<0.014). Tubgcp4KO/+ embryos were morphologically indistinguishable from wildtype (WT) embryos. Tubgcp4KO/+ and WT littermates were aged for 18 months to evaluate for susceptibility to retinal degeneration. There were no significant differences between these genotypes in ERG amplitudes or implicit times, retinal anatomy, or retinal thickness. Tubgcp4KO/+ retinal flat mounts revealed no vascularization defect. Mice heterozygous for the Tubgcp4cgt/+ allele were intercrossed. Embryonic lethality of Tubgcp4cgt/cgt mice was also observed (p< 6.7x10-5), and heterozygous mice were observed in expected ratios. The Tubgcp4cgt allele was therefore converted to the Tubgcp4fl allele to enable tissue- or time-specific conditional KO mice, which are in generation.

Conclusions : Two novel models targeting Tubgcp4 (Tubgcp4KO/KO and Tubgcp4cgt/cgt) demonstrate embryonic lethality. Initial characterization of heterozygous mice did not reveal evidence of haploinsufficiency, in contrast to a prior report. The conditional Tubgcp4 KO mice should allow mechanistic studies of microcephaly and chorioretinopathy induced by TUBGCP4 loss.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×